MPO and metabolic dysfunction-associated steatohepatitis: Administration of oral MPO inhibitor (2-thioxanthine AZM198) to obese hypertensive (induced by an HFD and ATII infusion) C57BL/6J mice reduced elevated MPO levels to normal values, ameliorated body weight gain, fat accumulation, reduced visceral adipose tissue inflammation, and the severity of nonalcoholic steatohepatitis [182].